Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for portal hypertension in compensated advanced chronic liver disease (TECA)
2024-513351-33-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic liver disease (CLD) and Portal Hypertension (PH) comparing Telmisartan arm with Placebo arm (2 arms). Primary endpoint: Change in hepatic venous pressure gradient at week 12. Planned start Jan 2025; status: authorised.
02
Drugs
telmisartan
03
Conditions
chronic liver disease (CLD)Portal Hypertension (PH)
Beyond the preview
Go deeper on 2024-513351-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513351-33-00.